Literature DB >> 16641460

Streptococcus pneumoniae isolates resistant to telithromycin.

M Rantala1, M Haanperä-Heikkinen, M Lindgren, H Seppälä, P Huovinen, J Jalava.   

Abstract

The telithromycin susceptibility of 210 erythromycin-resistant pneumococci was tested with the agar diffusion method. Twenty-six erm(B)-positive isolates showed heterogeneous resistance to telithromycin, which was manifested by the presence of colonies inside the inhibition zone. When these cells were cultured and tested, they showed stable, homogeneous, and high-level resistance to telithromycin.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16641460      PMCID： PMC1472201          DOI： 10.1128/AAC.50.5.1855-1858.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  23 in total

1.  Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.

Authors:  T A Davies; L M Kelly; M R Jacobs; P C Appelbaum
Journal:  J Clin Microbiol       Date:  2000-04       Impact factor: 5.948

2.  Prevalence and molecular genetics of macrolide resistance among Streptococcus pneumoniae isolates collected in Finland in 2002.

Authors:  M Rantala; S Huikko; P Huovinen; J Jalava
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

3.  A sequencing method based on real-time pyrophosphate.

Authors:  M Ronaghi; M Uhlén; P Nyrén
Journal:  Science       Date:  1998-07-17       Impact factor: 47.728

4.  Molecular characterization of the first telithromycin-resistant Streptococcus pneumoniae isolate in Germany.

Authors:  Ralf René Reinert; Mark van der Linden; Adnan Al-Lahham
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

5.  Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage.

Authors:  A Tait-Kamradt; T Davies; M Cronan; M R Jacobs; P C Appelbaum; J Sutcliffe
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

6.  In vitro activity of the new ketolide telithromycin compared with those of macrolides against Streptococcus pyogenes: influences of resistance mechanisms and methodological factors.

Authors:  P Bemer-Melchior; M E Juvin; S Tassin; A Bryskier; G C Schito; H B Drugeon
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Activity of telithromycin against penicillin-resistant Streptococcus pneumoniae isolates recovered from French children with invasive and noninvasive infections.

Authors:  Edouard Bingen; Catherine Doit; Chawki Loukil; Naima Brahimi; Philippe Bidet; Dominique Deforche; Pierre Geslin
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

Review 8.  Will resistance to ketolides develop in Streptococcus pneumoniae?

Authors:  R Leclercq
Journal:  J Infect       Date:  2002-02       Impact factor: 6.072

9.  Telithromycin-resistant Streptococcus pneumoniae.

Authors:  Fred Goldstein; Barbara Vidal; Marie D Kitzis
Journal:  Emerg Infect Dis       Date:  2005-09       Impact factor: 6.883

10.  Mutation at the position 2058 of the 23S rRNA as a cause of macrolide resistance in Streptococcus pyogenes.

Authors:  Jari Jalava; Martti Vaara; Pentti Huovinen
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-05-06       Impact factor: 3.944
View more
  6 in total

1.  Telithromycin-nonsusceptible clinical isolates of Streptococcus pneumoniae from Europe.

Authors:  Adnan Al-Lahham; Peter C Appelbaum; Mark van der Linden; Ralf René Reinert
Journal:  Antimicrob Agents Chemother       Date:  2006-11       Impact factor: 5.191

2.  Molecular epidemiology of telithromycin-resistant pneumococci in Finland.

Authors:  Merja Rantala; Sofia Nyberg; Marianne Lindgren; Pentti Huovinen; Jari Jalava; Reetta Skyttä; Laura Teirilä; Anni Vainio; Anni Virolainen-Julkunen; Tarja Kaijalainen
Journal:  Antimicrob Agents Chemother       Date:  2007-02-26       Impact factor: 5.191

3.  In vitro activity of CEM-101 against Streptococcus pneumoniae and Streptococcus pyogenes with defined macrolide resistance mechanisms.

Authors:  Pamela McGhee; Catherine Clark; Klaudia M Kosowska-Shick; Kensuke Nagai; Bonifacio Dewasse; Linda Beachel; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2009-11-02       Impact factor: 5.191

Review 4.  Newer antibacterial drugs for a new century.

Authors:  Gina Devasahayam; William M Scheld; Paul S Hoffman
Journal:  Expert Opin Investig Drugs       Date:  2010-02       Impact factor: 6.206

5.  Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.

Authors:  Lotta Siira; Merja Rantala; Jari Jalava; Antti J Hakanen; Pentti Huovinen; Tarja Kaijalainen; Outi Lyytikäinen; Anni Virolainen
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

Review 6.  Benefit-risk assessment of telithromycin in the treatment of community-acquired pneumonia.

Authors:  Steven D Brown
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.